Susanne F. Awad
Copenhagen, 2500, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL Trial.
Journal: Pain and therapy
Published: December 16, 2025
Sustained Efficacy of Eptinezumab in Participants with Migraine for Whom Prior Preventive Treatments Failed and Who Self-reported Psychiatric Comorbidities: Post Hoc Analysis of the Placebo-controlled DELIVER Trial.
Journal: Neurology and therapy
Published: November 13, 2025
Associations between good days per month and migraine-related disease impact in the real-world: a post hoc analysis from the REVIEW study of eptinezumab in chronic migraine.
Journal: The journal of headache and pain
Published: October 06, 2025
Long-Term Improvements Following Initial Migraine Response in Eptinezumab-Treated Participants With Migraine for Whom 2-4 Prior Preventive Treatments Have Failed.
Journal: European journal of neurology
Published: September 26, 2025
Real-world effectiveness of eptinezumab in chronic migraine-increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog.
Journal: The journal of headache and pain
Published: July 03, 2025
Early and Sustained Shift in Headache Day Frequency Following Eptinezumab Treatment in Adults With Migraine for Whom 2-4 Previous Preventive Treatments Have Failed: A Post Hoc Analysis of the Randomized DELIVER Trial.
Journal: European journal of neurology
Published: July 02, 2025
Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have Failed.
Journal: Advances in therapy
Published: June 11, 2025
Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial.
Journal: Journal of patient-reported outcomes
Published: February 08, 2024
Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab.
Journal: The journal of headache and pain
Published: January 30, 2024
An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity.
Journal: The journal of headache and pain
Published: December 22, 2023
Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: May 31, 2023
Showing 1-11 of 11
Last Updated: 09/26/2026